



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

053
SA
PATENTS

Applicant: Alani, et al.

Serial No.: 09/576,097

Filed: May 22, 2000

For: IMPROVED PHARMACEUTICAL
FORMULATIONS

Case No.: 6499.US.02

RECEIVED

MAR 03 2003

TECH CENTER 1600/2900

Commissioner for Patents
Washington D.C. 20231

Group Art No.: 1653

Examiner: D. Lukton

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: February 3, 2003

Tanya Parent

2/3/03

Date

RECEIVED

APR 06 2004

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled IMPROVED PHARMACEUTICAL FORMULATIONS are the following:

1. Amendment and Response with Marked-Up Version of Claims (32 pages);
2. Associate Power of Attorney;
3. Request for Three-Month Extension of Time, in duplicate; and
4. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



23492

ABBOTT LABORATORIES
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Respectfully submitted,
Alani, et al.

Kalim S. Fuzail
Registration No. 45,805
Attorney for Applicants



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alani, *et al.*

Group Art No.: 1653

Serial No.: 09/576,097

Examiner: D. Lukton

Filed: May 22, 2000

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

For: IMPROVED PHARMACEUTICAL
FORMULATIONS

Commissioner for Patents
Washington, D.C. 20231, on:

Case No.: 6499.US.02

Date of Deposit, February 3, 2003

Tanya Parent 2/3/03

Date

Commissioner for Patents
Washington D.C. 20231

RECEIVED

AMENDMENT AND RESPONSE

MAR 03 2003

Dear Sir:

TECH CENTER 1600/2900

In response to the Office Action dated August 9, 2002, please amend the application as follows:

IN THE CLAIMS

Please amend the claims as follows:

1. (twice amended) A pharmaceutical composition comprising:

- (a) solubilized (2S,3S,5S)-5-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinylamino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of solubilized (2S,3S,5S)-5-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinylamino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from about 1 to about 50 weight % of the composition;
- (b) a pharmaceutically acceptable organic solvent which comprises a medium and/or long chain fatty acid or a mixture thereof in an amount of from about 40 to about 75 weight % of the